Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2010
03/24/2010CN100595278C Genic engineering strain of expression recombinant prawn peptide Pen24 and its use
03/24/2010CN100595212C Interleukin-10 antibodies
03/24/2010CN100595210C Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof.
03/24/2010CN100595208C Production of sulfating fibroin protein and its use in anticoagulant
03/24/2010CN100594947C Bone graft and scaffolding materials immobilized with osteogenesis enhancing peptides on the surface
03/24/2010CN100594934C Amended recombinant cells (ARCs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants
03/24/2010CN100594932C Tumor necrosis factor antagonists and their use in endometriosis
03/24/2010CN100594930C Medicinal composition using anterior pituitary adrenal cortical extract as main component, and its preparation method and use
03/24/2010CN100594929C Oral insulin medicine and preparation method thereof
03/24/2010CN100594884C Recombination human interferon injection
03/23/2010US7684361 Method for controlling connections to a mobile station
03/23/2010US7683238 Preparing transgenic plants for use as bioreactors in generation of therapeutic proteins; pharmacogenetics
03/23/2010US7683159 Tenascin-W compositions and uses thereof
03/23/2010US7683059 Triazole compounds and uses related thereto
03/23/2010US7683038 Such as gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivativesl; for use in the pharmaceutical, biomedical, surgical and healthcare fields
03/23/2010US7683034 Use of enzyme inhibitors of aminopeptidase N and/or dipeptidylpeptidase IV
03/23/2010US7683033 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
03/23/2010US7683032 for treatment of infectious and inflammatory diseases, female fertility disorders, autoimmune disorders, tumors
03/23/2010US7683031 for stimulation of angiogenesis
03/23/2010US7683030 Methods of treating diabetes with albumin-conjugated exendin peptides
03/23/2010US7683029 high volatility carrier which protects the insulin from thermal degradation upon vaporization, particularly ethanol and water; propellant free.
03/23/2010US7683028 Particularly Kahalalide F, a tridecapeptide with a ring shape side and a lateral side amidated with 5-methylhexanoic acid; anticarcinogenic agent; refractory cancer that does not respond favorably to other treatments; peptides isolated mollusc, Elysia Elysia rufescens and its diet, a green algae
03/23/2010US7683027 preparations of insulin and glucagon; for use when glucagon response to acute hypoglycemia is impaired or lost in patients with advanced Type 1 and Type 2 diabetes
03/23/2010US7683026 can be implemented with any of the stereoisomers of each of the Lysine (K), Proline (P) or Valine (V) amino acid residues
03/23/2010US7683025 micelles; for loading or encapsulating polar drugs, DNA, mineralizable inorganic salts, and for small water-filled ion-conducting channels within their structure suitable for use in micro electromechanical devices,
03/23/2010US7683024 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
03/23/2010US7682808 Coagulation and fibrinolytic cascades modulator
03/23/2010US7682804 Diagnostics and therapeutics for macular degeneration-related disorders
03/23/2010US7682787 Using UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) to identify modulators for prevention and treatment of familial tumoral calcinosis (FTC)
03/23/2010US7682632 Tamper-resistant oral opioid agonist formulations
03/23/2010US7682631 Adhesin-specific nanoparticles and process for using same
03/23/2010US7682627 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
03/23/2010US7682625 Comprising hydrolyzed gelatin/tryptophan and ingestible carrier; for decubitus ulcers/bariatric surgery
03/23/2010US7682624 Method for treating wounds to promote healing
03/23/2010US7682612 Chronic Lymphocytic Leukemia (CLL) is treated with antibodies directed against the CD20 antigen; rituximab; chemotherapy
03/23/2010US7682351 Method for infusing insulin to a subject to improve impaired hepatic glucose processing
03/23/2010CA2607237C The use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy
03/23/2010CA2482865C Device for mixing and/or injecting cements
03/23/2010CA2389745C Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
03/23/2010CA2380951C Pharmaceutical compositions for oral and topical administration
03/23/2010CA2377783C Epitopes formed by non-covalent association of conjugates
03/23/2010CA2377278C Prodrugs of carbamate inhibitors of impdh
03/23/2010CA2372994C Implantable gel compositions and method of manufacture
03/23/2010CA2360795C Therapeutic compositions containing glutathione analogs
03/23/2010CA2356737C Tumor necrosis factor antagonists and their use in endometriosis
03/23/2010CA2353523C Allo and auto-reactive t-cell epitopes
03/23/2010CA2346869C Phospholipid derivatives of non-steroidal anti-inflammatory drugs
03/23/2010CA2332608C Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
03/23/2010CA2332488C Cells and animals deficient in protein kinase c epsilon
03/23/2010CA2325386C Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
03/23/2010CA2309639C Small peptides and methods for treatment of asthma and inflammation
03/23/2010CA2290724C Glycopeptide hexapeptides
03/23/2010CA2223412C Method for prolonging the expression of a gene of interest using soluble ctla4 molecules
03/23/2010CA2209124C Antitumor agent effect enhancer containing il-6 antagonist
03/23/2010CA2203655C Tumor necrosis factor-gamma
03/23/2010CA2201774C Multi-faceted method to repress reproduction of latent viruses in humans and animals
03/23/2010CA2194797C Nucleic acid containing composition, preparation and uses of same
03/23/2010CA2176927C Transparent liquid for encapsulated drug delivery
03/23/2010CA2172906C Biocompatible adhesive compositions
03/23/2010CA2149818C Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
03/18/2010WO2010031043A2 Reducing or preventing neuroinflammation or neurotoxicity
03/18/2010WO2010030840A2 Novel receptor and uses thereof
03/18/2010WO2010030790A2 Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
03/18/2010WO2010030789A1 Device and method for inhibiting complement activation
03/18/2010WO2010030670A2 Compositions and methods for the prevention of oxidative degradation of proteins
03/18/2010WO2010030653A2 Nurr1 interacting protein (nuip)
03/18/2010WO2010030359A2 Macrocyclic hepatitis c serine protease inhibitors
03/18/2010WO2010030317A2 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
03/18/2010WO2010030180A2 Peptide formulations and uses thereof
03/18/2010WO2010029546A2 Compositions and methods for treating s.pneumoniae infection
03/18/2010WO2010029545A2 Compositions and methods for treating s. pneumoniae infection
03/18/2010WO2010029453A1 Composition of thrombolytic agent and anti thrombosis and also its production method
03/18/2010WO2010029422A1 Novel dipeptidyl peptidase (dp-iv) compounds
03/18/2010WO2010029196A1 Antibacterial peptide compounds
03/18/2010WO2010029178A1 Factor ix polypeptide mutant, its uses and a method for its production
03/18/2010WO2010029162A1 Complement proteins
03/18/2010WO2010029158A1 Aplidine in the treatment of chronic myeloproliferative disorders
03/18/2010WO2010029104A2 Use of a pharmaceutical composition for the local treatment of infections, and medical product
03/18/2010WO2010028845A2 Use of an ang-(1-7) receptor agonist in acute lung injury
03/18/2010WO2010028770A1 A chemodenervating agent to introduce temporal infertility in a vertebrate (e.g. human)
03/18/2010WO2010028676A1 Use of a peptide as a therapeutic agent
03/18/2010WO2010028675A1 Use of tyrosinase ( 192-200 ) nonapeptide as a therapeutic agent
03/18/2010WO2010028674A1 Use of a peptide as a therapeutic agent
03/18/2010WO2010028673A1 Use of a peptide as a therapeutic agent
03/18/2010WO2010028672A1 Use of a peptide as a therapeutic agent
03/18/2010WO2010028671A1 Use of opiorphin as a therapeutic agent
03/18/2010WO2010028651A2 Method of upregulating sorla for the treatment of alzheimer's disease
03/18/2010WO2010028503A1 Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
03/18/2010WO2010028432A1 Protocols for treating bone disorders
03/18/2010WO2010014812A3 Peptide compositions and methods of use
03/18/2010WO2010003601A8 Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use
03/18/2010WO2009158704A3 Therapeutic agents comprising elastin-like peptides
03/18/2010WO2009158409A3 Pimap39 modulates inflammatory response
03/18/2010WO2009154697A3 Disc-1 pathway activators in the control of neurogenesis
03/18/2010WO2009153458A3 Cyclized non-native synthetic peptide and complex of peptides comprising said cyclized peptide, intended to induce and to characterize the prevention or treatment of conditions in mammals
03/18/2010WO2009152453A3 Compositions and methods for treating pulmonary hypertension
03/18/2010WO2009140039A3 Synthetic antibodies
03/18/2010WO2009137091A3 Catestatin (cst) and its variants for treatment of cardiovascular and metabolic disorders
03/18/2010WO2009134380A8 Super fast-acting insulin compositions
03/18/2010WO2009132149A3 Treatment of conditions related to cecal ligation shock
1 ... 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 ... 3163